Good Health Can’t Wait.

More documents

Recommendations

Info

Good Health Can’t Wait. Dr. Reddy’s Laboratories Limited NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated) 2.30: RELATED PARTY DISCLOSURES (CONTINUED) b. List of Key Management Personnel* of the Company K Satish Reddy (whole-time director); Dr. Raghav Chari; G V Prasad (whole-time director); Dr. KVS Ram Rao; Abhijit Mukherjee; M V Ramana; Alok Sonig; Samiran Das; Dr. Amit Biswas; Sandeep Poddar; Dr. R Ananthanarayanan (till 30 November 2014); Saumen Chakraborty; and Dr. Cartikeya Reddy; Umang Vohra. Dr. Chandrasekhar Sripada; * In accordance with the provisions of AS 18 “Related Party Disclosures” and the Companies Act, 2013, members of the Company’s Management Council and Company Secretary are considered as Key Management Personnel. c. Particulars of related party transactions The following is a summary of significant related party transactions: PARTICULARS FOR THE YEAR ENDED 31 MARCH 2015 FOR THE YEAR ENDED 31 MARCH 2014 i. Sales of raw materials to Ecologic Chemicals Limited - 49 ii. Sale of assets to Ecologic Chemicals Limited - 14 iii. Purchases and services from: Ecologic Chemicals Limited 5 91 Dr. Reddy’s Institute of Life Sciences 92 96 Total 97 187 iv. Contributions for social development: Dr. Reddy’s Foundation 207 143 Pudami Educational Society 30 27 Total 237 170 v. Purchase of assets from Ecologic Chemicals Limited (refer note 2.39) - 1,264 vi. Hotel expenses paid/ payable to: Green Park Hotel and Resorts Limited 32 20 Stamlo Hotels Private Limited 9 11 Total 41 31 vii. Rent paid/ payable to: Key management personnel K Satish Reddy 14 14 Relatives of key management personnel G Anuradha 13 13 Deepti Reddy 3 3 K Samrajyam 2 2 G Mallika Reddy 2 2 G V Sanjana Reddy 2 2 Total 22 22 viii. Rental deposit paid to: Relatives of key management personnel G Mallika Reddy - 2 G V Sanjana Reddy - 2 Total - 4 202
Consolidated Financial Statements Annual Report 2014 - 15 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (All amounts in Indian Rupees millions, except share data and where otherwise stated) 2.30: RELATED PARTY DISCLOSURES (CONTINUED) PARTICULARS FOR THE YEAR ENDED 31 MARCH 2015 FOR THE YEAR ENDED 31 MARCH 2014 ix. Remuneration to key management personnel (1)(2) 526 476 (1) The above amounts do not include stock compensation expense. (2) In addition to the above, the Company has accrued an amount of ` 67 towards a long term incentive plan, for the services rendered by key management personnel during the year ended 31 March 2015. Refer to Note 2.35 for further details. d. The Company has the following dues from / to related parties: PARTICULARS AS AT 31 MARCH 2015 AS AT 31 MARCH 2014 i. Due from related parties: Rental deposit to key management personnel and their relatives 8 8 ii. Due to related parties (included in trade payables and other current liabilities): Dr. Reddy’s Research Foundation 18 18 Green Park Hotels & Resorts Limited 1 - Dr. Reddy’s Institute of Life Sciences 3 - Total 22 18 2.31: SEGMENT REPORTING The primary and secondary reportable segments are business and geographic segments, respectively. Business segments: The Company is organised on a worldwide basis into the following businesses which are reportable segments: Pharmaceutical Services and Active Ingredients (“PSAI”); Global Generics; and Proprietary Products. Pharmaceutical Services and Active Ingredients: This segment includes active pharmaceutical ingredients and intermediates, also known as active pharmaceutical products or bulk drugs, which are the principal ingredients for finished pharmaceutical products. Active pharmaceutical ingredients and intermediates become finished pharmaceutical products when the dosages are fixed in a form ready for human consumption such as a tablet, capsule or liquid using additional inactive ingredients. This segment also includes contract research services and the manufacture and sale of active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Global Generics: This segment consists of finished pharmaceutical products ready for consumption/ use by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). This segment includes the operations of the Company’s biologics business. Proprietary Products: This segment consists of the Company’s differentiated formulations business, New Chemical Entities (“NCEs”) business, and the dermatology focused specialty business operated through Promius Pharma. Others: This includes the operations of the Company’s wholly-owned subsidiary, Aurigene Discovery Technologies Limited, a discovery stage biotechnology company developing novel and best-in-class therapies in the fields of oncology and inflammation and which works with established pharmaceutical and biotechnology companies in early-stage collaborations, bringing drug candidates from hit generation through Investigational New Drug (“IND”) filing. Geographic segments: The Company’s business is organised into five key geographic segments viz. India, North America, Russia and other CIS countries, Europe and Others. Revenues are attributable to individual geographic segments based on the location of the customer. Segment revenues and expenses: All segment revenues and expenses are directly attributable to the segments. Segment assets and liabilities: As certain assets of the Company including manufacturing facilities, development facilities, and treasury assets and liabilities are often deployed interchangeably across business segments, it is impractical to allocate these assets and liabilities to each business segment. Inter-segment transfers: Segment revenue, segment expenses and segment result include transfers between business segments. Inter-segment transfers are accounted for at cost to the transferring segment. Such transfers are eliminated on consolidation. 203
Page 1 and 2:
ANNUAL REPORT 2014-15 Good Health C
Page 3 and 4:
Our Brand We are in the business of
Page 5 and 6:
Corporate Overview Annual Report 20
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Statutory Reports • Business Resp
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Statutory Reports • Management Di
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Statutory Reports • Corporate Gov
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Statutory Reports • Additional Sh
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Statutory Reports • Board’s Rep
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Standalone Financial Statements Ann
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154: Standalone Financial Statements Ann
Page 165 and 166: Consolidated Financial Statements A
Page 203: Consolidated Financial Statements A
Page 227 and 228: Notice Annual Report 2014 - 15 NOTI
Page 229 and 230: E-Voting Annual Report 2014 - 15 IN
Page 231: Dr. Reddy’s Laboratories Limited
Page 235 and 236: The future belongs, not to those wh
show all

Good Health Can’t Wait.

Create successful ePaper yourself

Delete template?

Save as template?